<DOC>
	<DOCNO>NCT00112242</DOCNO>
	<brief_summary>The purpose study determine whether vaccination melanoma antigen peptide [ Melan-A/Mart-1 ( EAA ELA ) , NY-ESO-1b analog , Long NY-ESO-1 LP MAGE-A10 ] Montanide , CpG adjuvants low dose rIL-2 induce immune response melanoma patient assess safety vaccination .</brief_summary>
	<brief_title>Immunotherapy Stage III/IV Melanoma Patients</brief_title>
	<detailed_description>Current peptide vaccine suffer low efficiency , since induce weak immune activation . We recently confirm human immune response readily detectable local lymph node weak activation could identify circulate lymphocyte . Increased dos antigen adjuvant allow good extension local systemic immune response . - Group 1 : vaccination Melan-A analog ( ELA ) peptide + Montanide - Group 2 : vaccination Melan-A analog ( ELA ) , NY-ESO-1b analog MAGE-A10 peptide + Montanide - Group 3 : vaccination Melan-A analog ( EAA ELA ) , Mage-A10 , NY-ESO-1 peptides+ Montanide + CpG adjuvant - Group 4 : vaccination Melan-A ( ELA ) , Mage-A10 , long NY-ESO-1LP peptide + Montanide + CpG - Group 5 : vaccination Melan-A ( EAA ELA ) , Mage-A10 , long NY-ESO-1 LP peptides + Montanide + CpG + low dose rIL-2</detailed_description>
	<mesh_term>Melanoma</mesh_term>
	<criteria>Histologically confirm stage III stage IV melanoma Tumor expression MelanA +/ one tumor antigens MAGEA10 , NYESO1 , LAGE1 Human leukocyte antigenA2 ( HLAA2 ) positive Clinically significant heart disease Serious illnesses , eg , serious infection require antibiotic , uncontrolled peptic ulcer , central nervous system disorder History immunodeficiency disease autoimmune disease Coagulation bleeding disorder</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>April 2013</verification_date>
	<keyword>Immunotherapy</keyword>
	<keyword>Vaccination</keyword>
	<keyword>Melanoma</keyword>
	<keyword>Melan-A/Mart-1 peptide</keyword>
	<keyword>MAGE-A10 peptide</keyword>
	<keyword>NY-ESO-1 peptide</keyword>
	<keyword>Montanide</keyword>
</DOC>